Zombie UV™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Zombie_UV_Viability_Dye_012714
One day old C57BL/6 mouse splenocytes were stained with Zombie UV™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie UV™ staining, are indicated in black.
  • Zombie_UV_Viability_Dye_012714
    One day old C57BL/6 mouse splenocytes were stained with Zombie UV™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie UV™ staining, are indicated in black.
See Zombie UV™ spectral data
Cat # Size Price Quantity Check Availability
423107 100 tests $89.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423108 500 tests $335.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie UV™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie UV™ is a polar water soluble dye, providing violet fluorescence, making it suitable for multi-color detection.

Technical data sheet

Product Details

Preparation
Zombie UV™ Fixable Viability kit is composed of lyophilized Zombie UV™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie UV™ dye until fully dissolved. 100 tests = 1 vial of Zombie UV™ + DMSO, 500 tests = 5 vials of Zombie UV™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie UV™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser
Ultraviolet Laser (355 nm)
Application Notes

Zombie UV™ dye is excited by the UV laser (355 nm) and has fluorescence emission maximum at 459 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie UV™ dye has similar emission to DAPI.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie UV™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie UV™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µl Zombie UV™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µl for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  5. Incubate the cells at room temperature, in the dark, for 15-30 minutes.
  6. Wash one time with 2 ml BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie UV™ dye and mix until fully  dissolved
  3. Determine the total µl volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µl. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie UV™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µl of antibody cocktail for a 100 µl total staining volume, use 80 µl of Zombie UV™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie UV™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  4. Incubate for 10-15 minutes at RT, protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.


Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie UV™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie UV™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie UV™.

 

Application References

(PubMed link indicates BioLegend citation)
  1. Souza-Fonesca-Guimaraes F, et al. 2015. PNAS. 112:2376. PubMed
Product Citations
  1. Zgair A, et al. 2017. Sci Rep. . 10.1038/s41598-017-15026-z. PubMed
  2. Souza-Fonseca-Guimaraes F, et al. 2016. Cell Death Dis. 7:e2302. PubMed
  3. Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed
  4. Reyes RA, et al. 2021. PLoS One. 16:e0261656. PubMed
  5. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  6. Tocheva AS, et al. 2020. Curr Protoc Immunol. 130:e103. PubMed
  7. Duraiswamy J, et al. 2021. Cancer Cell. 39:1623. PubMed
  8. Klapholz M, et al. 2022. J Pathol. 257:186. PubMed
  9. Alam A, et al. 2022. Cancer Cell. 40:153. PubMed
  10. Huang SSY, et al. 2022. J Cell Mol Med. 26:1714. PubMed
  11. Atalis A, et al. 2022. J Control Release. 347:476. PubMed
  12. Xu C, et al. 2022. iScience. 25:105123. PubMed
  13. Weng S, et al. 2022. Front Immunol. 13:1025931. PubMed
  14. Tatsumi N, et al. 2022. STAR Protoc. 3:101845. PubMed
  15. Giannou AD, et al. 2023. Immunity. 56:125. PubMed
  16. Mallick S, et al. 2023. Transl Res. :. PubMed
  17. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  18. Smith LA, et al. 2023. Front Oncol. 12:1031174. PubMed
  19. Denis M, et al. 2023. Front Immunol. 13:1011943. PubMed
  20. Labuz DR, et al. 2023. Elife. 12: . PubMed
  21. Shen JZ, et al. 2022. Mol Cell. 82:1123. PubMed
  22. Zhang H, et al. 2022. J Exp Med. 219:. PubMed
  23. Arruda DC, et al. 2022. J Control Release. 350:228. PubMed
  24. Michaels YS, et al. 2022. Sci Adv. 8:eabn5522. PubMed
  25. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  26. Bonadonna M, et al. 2022. Sci Adv. 8:eabq4469. PubMed
  27. Humphries DC, et al. 2023. Front Immunol. 14:1100161. PubMed
  28. Heng Y, et al. 2023. J Transl Med. 21:167. PubMed
  29. Yi X, et al. 2023. Signal Transduct Target Ther. 8:107. PubMed
  30. Gu XW, et al. 2023. Nat Commun. 14:1439. PubMed
  31. Arunachalam PS, et al. 2023. J Clin Invest. 133:. PubMed
  32. Hackerova L, et al. 2023. Front Vet Sci. 10:1116891. PubMed
  33. Kak G, et al. 2023. J Neuroinflammation. 20:114. PubMed
  34. Lin W, et al. 2023. Commun Biol. 6:447. PubMed
  35. Borbet TC, et al. 2023. iScience. 26:106810. PubMed
  36. Wang X, et al. 2023. Stem Cell Rev Rep. . PubMed
  37. Xu H, et al. 2017. EBioMedicine. 10.1016/j.ebiom.2017.03.003. PubMed
  38. Lu C, et al. 2019. Cancer Immunol Res. 7:414. PubMed
  39. Clarke F,et al. 2017. PLoS One. 10.1371/journal.pone.0186625. PubMed
  40. Matsui K, et al. 2015. PLoS One. 10: 0137195. PubMed
  41. Vaughan HJ, et al. 2021. Mol Ther Oncolytics. 21:377. PubMed
  42. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  43. Trimaglio G, et al. 2020. Oncoimmunology. 9:1790125. PubMed
  44. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  45. Rafiq S, et al. 2018. Nat Biotechnol. 36:847. PubMed
  46. Souza-Fonseca-Guimaraes F, et al. 2015. Proc Natl Acad Sci U S A. 112:2376. PubMed
  47. Rao S, et al. 2017. Cell. 168(3):503-516.e12. PubMed
  48. Godbersen-Palmer C, et al. 2020. J Immunol. 204:2973. PubMed
  49. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  50. Poggio M, et al. 2019. Cell. 177:414. PubMed
  51. Leigh N, et al. 2017. The Journal of Immunology. 10.4049/jimmunol.1502181. PubMed
  52. An J,et al. 2017. Sci Rep.. 10.1038/s41598-017-13629-0. PubMed
  53. Sellau J, et al. 2020. Nat Commun. 2.860416667. PubMed
  54. Odeh-Couvertier VY, et al. 2022. Bioeng Transl Med. 7:e10282. PubMed
  55. Vanshylla K, et al. 2022. Cell Host Microbe. 30:69. PubMed
  56. Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed
  57. Zhang X, et al. 2022. Cell Rep. 40:111203. PubMed
  58. Reighard SD, et al. 2020. Cell Rep Med. :1. PubMed
  59. Lin J, et al. 2017. Sci Rep. 7:41722. PubMed
  60. Lord JD, et al. 2018. Clin Immunol. 193:24:00. PubMed
  61. Nath PR, et al. 2019. Cancer Immunol Res. 7:1547. PubMed
  62. Fallet B, et al. 2020. Cell Rep. 30:1013. PubMed
  63. Littwitz-Salomon E, Schimmer S, and Dittmer U. 2017. J Virol. 10.1128/JVI.01122-17. PubMed
  64. Kallert S, et al. 2017. Nature Communications. 10.1038/ncomms15327. PubMed
  65. Moreno-Fernandez ME, et al. 2018. JCI Insight. 3. PubMed
  66. Li D, et al. 2019. J Lipid Res. 60:1503. PubMed
  67. Trüb M, et al. 2020. J Immunother Cancer. 8:00. PubMed
  68. Shiao SL, et al. 2021. Cancer Cell. 39:1202. PubMed
  69. Lerrer S, et al. 2021. iScience. 24:103020. PubMed
  70. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
  71. Gehling K, et al. 2022. Life Sci Alliance. 5:. PubMed
  72. Nath PR, et al. 2022. Oncoimmunology. 11:2111909. PubMed
  73. Truong AS, et al. 2021. J Clin Invest. 131:. PubMed
  74. Kalbasi A, et al. 2020. Sci Transl Med. :12. PubMed
  75. Huang SSY, et al. 2021. Biology. 10(8):. PubMed
  76. Zeng Y, et al. 2019. Oncotarget. 10:4479. PubMed
  77. Fredriksson-Lidman K, et al. 2017. PLoS One. 10.1371/journal.pone.0185509. PubMed
  78. O’Neill R, et al. 2017. J Immunol. 10.4049/jimmunol.1700380. PubMed
  79. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  80. Burns JC, et al. 2020. eLife. 9:00. PubMed
  81. Harder I, et al. 2022. Cells. 11:. PubMed
  82. McVey JC, et al. 2022. iScience. 25:103847. PubMed
  83. Den Braanker H, et al. 2021. Front Immunol. 12:768113. PubMed
  84. Ganguly S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:891. PubMed
  85. Henrich IC, et al. 2021. Cancer Res. 81:2171. PubMed
  86. Johnston S, et al. 2021. Elife. 10: . PubMed
  87. Smith CA, et al. 2019. JCI Insight. 4. PubMed
  88. Pasciuto E, et al. 2020. Cell. 182:625. PubMed
  89. Zhang R, et al. 2022. Front Pharmacol. 13:870848. PubMed
  90. Graciotti M, et al. 2020. Vaccines (Basel). 8:00. PubMed
  91. Capuccini B, et al. 2016. Sci Rep. 6:39258. PubMed
  92. Dangaj D, et al. 2019. Cancer Cell. 35:885. PubMed
  93. Lyle C, et al. 2019. Sci Rep. 9:20257. PubMed
  94. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  95. Moreno-Fernandez ME, et al. 2021. STAR Protoc. 2:100937. PubMed
  96. Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed
  97. Georg P, et al. 2022. Cell. 185:493. PubMed
  98. Ireland RE, et al. 2022. Viruses. 14:. PubMed
  99. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  100. Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed
  101. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  102. Nath PR, et al. 2019. Front Immunol. 9:2985. PubMed
  103. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
  104. Salehi S, et al. 2017. PLoS One. 10.1371/journal.pone.0163614. PubMed
  105. Mempin M, et al. 2021. Cancers (Basel). 13:. PubMed
  106. Wimmers F, et al. 2021. Cell. 184:3915. PubMed
  107. Galván-Peña S, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  108. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  109. Prosser A, et al. 2021. STAR Protoc. 2:100810. PubMed
  110. Grabiec A, et al. 2017. J Allergy Clin Immunol. 10.1016/j.jaci.2017.03.024. PubMed
  111. Giles D, et al. 2016. PLoS One. 11: 0149783. PubMed
  112. Lacar B, et al. 2016. Nat Commun. 7: 11022. PubMed
  113. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
  114. Lee A, et al. 2022. Nat Commun. 13:549. PubMed
  115. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  116. Zhong W, et al. 2022. Front Immunol. 13:1001255. PubMed
  117. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  118. Zeng Y, et al. 2019. FASEB J. 33:6596. PubMed
  119. Mitchell LA, et al. 2019. Oncotarget. 10:2252. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA
Go To Top Version: 4    Revision Date: 05/30/2019

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

Login/Register
Forgot your password? Reset Password
Request an Account